Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025Mesothelin named as second target in Radio-DARPin pipeline, program to be co-developed with...
-
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
-
MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity Clinical protocol amendment in process...
-
Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a...
-
Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial antileukemic and pharmacodynamic activity Switch-DARPin...
-
Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data expected...
-
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
-
Under the revised agreement, both companies will co-develop four Radio-DARPin programs; each company will have the right to commercialize two programs (previously one each)Molecular Partners will hold...
-
Dose-dependent efficacy observed with favorable safety profile Attractive tumor to kidney ratios shown in biodistribution studies Picomolar affinity and high specificity for DLL3 as precision...
-
Preclinical proof-of-concept data supports CD3 Switch-DARPin platform for T cell engagers with enhanced function in solid tumors Biomarker data on completed phase 1 study of MP0317 (FAP x CD40)...